DigestRedComo funciona
Red
/
Empresas
Je
No verificado

Jeito Capital

Sobre qué escribimos

Anuncios brevesBiotecnologíaFarmacéuticaFinanzasPublicidad/Marketing/Medios de comunicación/Comunicación

13 Comunicados de prensa

Ver todos los comunicados de prensa
14/04/2026
Biotecnología
Farmacéutica
Salud
Oncología
Jeito Capital leads oversubscribed $75 million Series C in Adcendo ApS to Advance its First- and Best-in-class Clinical ADC1 Pipeline in Oncology
Fuente
Jeito Capital
Editor
Business Wire
1.00
0
08/04/2026
Cardiología
Biotecnología
Farmacéutica
Oncología
Salud
Administración de Empresas
Asociaciones/Profesionales
Jeito Capital Hits Record $1.2 Billion (€1 Billion)1 Close for Jeito II Fund to Drive Breakthrough Therapeutic Innovation for Patients
Fuente
Jeito Capital
Editor
Business Wire
1.00
0
24/02/2026
Finanzas
Anuncios breves
Publicidad/Marketing/Medios de comunicación/Comunicación
Jeito Capital Makes Significant Investment in the Second Closing of Alveus Therapeutics’ Oversubscribed Series A, Bringing Total Financing to $197 Million
Fuente
Jeito Capital
Editor
GLOBENEWSWIRE
1.00
0
15/10/2025
Finanzas
Publicidad/Marketing/Medios de comunicación/Comunicación
Anuncios breves
Jeito Capital promotes Ksenija Pavletic to General Partner
Fuente
Jeito Capital
Editor
GLOBENEWSWIRE
1.00
0
10/09/2025
Finanzas
Anuncios breves
Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs
Fuente
Jeito Capital
Editor
GLOBENEWSWIRE
1.00
0
20/05/2025
Finanzas
Publicidad/Marketing/Medios de comunicación/Comunicación
Anuncios breves
Jeito Capital Leads a USD 65 million Financing in ReproNovo to Develop Transformational Treatments in Reproductive Medicine and Women’s Health
Fuente
Jeito Capital
Editor
GLOBENEWSWIRE
1.00
0
12/05/2025
Finanzas
Publicidad/Marketing/Medios de comunicación/Comunicación
Anuncios breves
Jeito Capital leads EUR 132 million oversubscribed Series B financing in Azafaros to advance Phase 3 clinical programs of innovative therapies in rare inherited neuro-metabolic disorders
Fuente
Jeito Capital
Editor
GLOBENEWSWIRE
1.00
0
11/05/2025
Finanzas
Anuncios breves
Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal
Fuente
Jeito Capital
Editor
GLOBENEWSWIRE
1.00
0
23/03/2025
Finanzas
Publicidad/Marketing/Medios de comunicación/Comunicación
Anuncios breves
Jeito Capital co-leads the oversubscribed €78 million financing in Augustine Therapeutics to develop novel therapies for neuromuscular, cardio-metabolic and neurodegenerative diseases
Fuente
Jeito Capital
Editor
GLOBENEWSWIRE
1.00
0
03/03/2025
Finanzas
Publicidad/Marketing/Medios de comunicación/Comunicación
Anuncios breves
Jeito Capital announces significant participation in $187 million Series A financing for Callio Therapeutics to advance innovative multi-payload ADC programs designed to maximize therapeutic benefit for cancer patients
Fuente
Jeito Capital
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0